Results 71 to 80 of about 190,081 (230)

Dimensiones de sensibilidad al asco y predicción diferencial de los síntomas fóbicos [PDF]

, 2013
The present study examines the association between disgust domains and phobic symptoms (i.e., fears and blood-injections symptoms) in a nonclinical sample (N = 580).
Sandín, Bonifacio, Valiente, Rosa M., Pineda, David, Santed, Miguel A., Chorot, Paloma   +4 more
core   +1 more source

Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?—Lessons From Value Assessment With ASCO-VF and ESMO-MCBS

Frontiers in Pharmacology, 2020
Background: Influx of innovative therapies and dramatic rise in prices have been prompting value-driven decision-making. Both the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have independently ...
Qian Jiang, Mei Feng, Youping Li, Jinyi Lang, Hua Wei, Hua Wei, Ting Yu   +6 more
doaj   +1 more source

CDK4/6 Inhibitors in the Management of Hormone Receptor‐Positive (HR+)/Human Epidermal Growth Factor Receptor 2‐Negative (HER2−) Advanced Breast Cancer in Indonesia: Challenges, Opportunities, and Recommendations

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Evidence‐informed recommendations emphasize the integration of CDK4/6 inhibitors with endocrine therapy as a central component in the management of HR+/HER2− advanced breast cancer in Indonesia. Expanding access and facilitating integration within national treatment frameworks are crucial to improve outcomes and reduce disparities in care.
Sonar Soni Panigoro, Samuel J. Haryono, Prihantono Prihantono, Dedy Hermansyah, Sumadi Lukman Anwar, Yohana Azhar, Febriyanto Kurniawan, Putu Anda Tusta Adiputra, Kristanto Yuli Yarso, Asdi Wihandono   +9 more
wiley   +1 more source

Clinical Relevance of the SOUND and INSEMA Trials in Women With Early Breast Cancer in Australia and New Zealand

ANZ Journal of Surgery, EarlyView.
ABSTRACT Background Axillary surgery in breast cancer has undergone progressive de‐escalation. The recent Sentinel Node versus Observation after Axillary Ultrasound (SOUND) and Intergroup Sentinel Mamma (INSEMA) trials have demonstrated that sentinel lymph node biopsy may be safely omitted in selected patients. This study aimed to evaluate the clinical
Matea Dominkovic, Kerry Hitos, Wei Wang, T. Michael Hughes, James French, Nicholas Ngui   +5 more
wiley   +1 more source

Global Equity in Clinical Trials: An ASCO Policy Statement

JCO Global Oncology
ASCO is a global professional society representing more than 50,000 physicians, other health care professionals, and advocates in over 100 countries specializing in cancer treatment, diagnosis, prevention, and advocacy.
Sana A. Al Sukhun, Verna Vanderpuye, Carolyn Taylor, Abiola Falilat Ibraheem, Andres Wiernik Rodriguez, Fredrick Chite Asirwa, Michael Francisco, Allyn Moushey   +7 more
doaj   +1 more source

The PSA test for prostate cancer screening: an abridged Cochrane review

BJU International, EarlyView.
Objectives To assess the effects of prostate cancer screening compared to no screening in men with no prior diagnosis of prostate cancer. Methods This systematic review represents an update of a prior Cochrane review from 2013, searching multiple databases up to November 2025. We included randomised controlled trials (RCTs) of prostate cancer screening
Juan V. A. Franco, Eu Chang Hwang, Jae Hung Jung, Octavio Vaimberg, Dragan Ilic, Anne Cleves, Philipp Dahm   +6 more
wiley   +1 more source

Molecular profiling of pediatric medulloblastoma in Kazakhstan: Genomic alterations, subgroup distribution, and survival

Brain Pathology, EarlyView.
A practical formalin‐fixed, paraffin‐embedded (FFPE)‐based molecular workflow integrating pathology, immunohistochemistry, and genomic profiling provides clinically meaningful subgroup classification of pediatric medulloblastoma and expands molecular evidence from an underrepresented Central Asian population. Abstract Medulloblastoma is the most common
Aidos Bolatov, Askhat Zhakupov, Aizhan Abdikadirova, Malika Sapargaliyeva, Bakytkali Ibraimov, Zhanat Zhalimbetova, Gabit Ólenbay, Berik Zhetpisbayev, Xingzhi Xu, Mirgul Bayanova   +9 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu, Lisa Zimmer, Dimitra Vlachopoulou, Elias Haj‐Yehia, Julia Hoffmann, Lars Michel, Elisabeth Livingstone, Dirk Schadendorf, Alpaslan Tasdogan, Matthias Totzeck, Tienush Rassaf   +10 more
wiley   +1 more source

Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer

Cancer Science, EarlyView.
Integrated analysis of 445 bladder cancers showed that HER2 membrane expression and ERBB2 amplification are distinct features. HER2 expression overlapped with NECTIN4 expression, whereas ERBB2 amplification was enriched in the LumU subtype and associated with poor prognosis.
Kensuke Hirosuna, Kazuki Nishimura, Moritoshi Sakamoto, Satoshi Tokushige, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Takeshi Tsutsumi, Ryoichi Maenosono, Takuya Tsujino, Masahiko Ajiro, Haruhito Azuma, Akihide Yoshimi, Kazumasa Komura   +13 more
wiley   +1 more source

Evolution of CAR‐T Therapy: Functional Engineering, Manufacturing Innovation, and Future In Vivo Strategies

Cancer Science, EarlyView.
CAR‐T therapy is evolving across four interconnected dimensions: functional engineering, manufacturing innovation, alternative cell sources, and in vivo CAR programming. Together, these advances address limitations in therapeutic efficacy, safety, manufacturing complexity, scalability, and accessibility, providing complementary paths toward the next ...
Yukimi Sakoda
wiley   +1 more source